Compare · HLF vs MEDS
HLF vs MEDS
Side-by-side comparison of Herbalife Ltd. (HLF) and DataMeds AI Inc. (MEDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HLF and MEDS operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- HLF is the larger of the two at $1.63B, about 391.2x MEDS ($4.2M).
- HLF has been more active in the news (10 items in the past 4 weeks vs 7 for MEDS).
- HLF has more recent analyst coverage (14 ratings vs 1 for MEDS).
- Company
- Herbalife Ltd.
- DataMeds AI Inc.
- Price
- -
- -
- Market cap
- $1.63B
- $4.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- 2004
- News (4w)
- 10
- 7
- Recent ratings
- 14
- 1
Herbalife Ltd.
Herbalife Nutrition Ltd. offers nutrition solutions in North America, Mexico, South and Central America, Europe, the Middle East, Africa, and the Asia Pacific. The company provides products in the areas of weight management; targeted nutrition; energy, sports, and fitness; and outer nutrition. It offers weight management products, including meal replacement products, protein shakes, drink mixes, weight loss enhancers, and healthy snacks; targeted nutrition products, which include functional beverages, and dietary and nutritional supplements that contain herbs, vitamins, minerals, and other natural ingredients; outer nutrition products, such as facial skin, body, and hair care products; and energy, sports, and fitness products comprising N-R-G tea and energy drink products. The company also provides literature, promotional, and other materials that include start-up kits, sales tools, and educational materials. It offers its products through independent service providers and sales representatives, as well as through company-operated retail platforms. The company was formerly known as Herbalife Ltd. and changed its name to Herbalife Nutrition Ltd. in April 2018. Herbalife Nutrition Ltd. was founded in 1980 and is headquartered in Los Angeles, California.
DataMeds AI Inc.
DataMEDS AI, Inc. (NASDAQ:MEDS), formerly Wellgistics Health, Inc., is a healthcare company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its health information technology platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates its EinsteinRx artificial intelligence platform and PharmacyChain blockchain-enabled smart contracts platform into the Health Lives Here mobile application from Tollo Health, LLC, and its pharmacy-related Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including distribution of products developed by Tollo Health. DataMEDS also owns Helomics Corporation, a Pittsburgh, PA -based commercial clinical molecular diagnostics laboratory focused on the ChemoFx Assay chemotherapy selection diagnostics test that aims to help oncologists make chemotherapy treatment decisions.
Latest HLF
- Herbalife Launches Fuel Her Power, a Nutrition Guide for Active Women
- Amendment: SEC Form SCHEDULE 13G/A filed by Herbalife Ltd.
- Interim CEO Desimone John was granted 34,593 stock appreciation rights (SEC Form 4)
- Chief Financial Officer Schaefer Scott Stephen was granted 3,391 stock appreciation rights (SEC Form 4)
- New insider Schaefer Scott Stephen claimed ownership of 2,500 shares (SEC Form 3)
- Herbalife to Participate in 1 on 1 Meetings at Stephens Annual Investment Conference on November 19
- NYSE-Affiliated Venue for Tokenization Adds Transfer Agents: NYSE Content Update
- Herbalife Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 10-Q filed by Herbalife Ltd.
- Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion
Latest MEDS
- DataMEDS AI Agrees to Acquire TBIA Cancer AI Blood Test Platform From Todos Medical Estate for Subsidiary Helomics, Inc.
- UPDATING ORIGINAL RELEASE DataMEDS AI Releases CEO Letter
- DataMEDS AI Releases CEO Letter
- DataMEDS AI Reports 50% Sequential Revenue Growth in Third Quarter 2026 From Second Quarter 2026, Delivers Net Profit Per Share of $2.72 and Provides Business Update
- DataMEDS AI Signs MOU to Deploy Health Lives Here GLP-1 Patient Management Program with Florida-Based HMO
- DataMEDS AI Announces Termination of Second Amended and Restated Letter of Intent
- DataMEDS AI Enters Into Agreement for Commercial Supply of Six Peptides Recommended by FDA Advisory Committee
- DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
- Datavault AI Signs Non-Binding Letter of Intent to Acquire a 19.9% Equity Stake in DataMEDS AI in Consideration of an Expanded Technology License
- DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies